@cmicomms.bsky.social📣 New #Communicable drops Mon 19 Oct!
Emily McDonald and Angela Huttner sit down for another Quarterly catch-up, discussing four recent RCTs across different patient populations and infections, and what the findings mean for clinical practice.
@cmicomms.bsky.social🎙️ Just published Communicable E64: Getting micro on macrolides for community-acquired pneumonia
Hosted by Marc Bonten & Emily McDonald with invited guests Valentijn Schweitzer & Sylvain Lother 🌟
Listen on #Communicable: https://share.transistor.fm/s/deec5589
@cmicomms.bsky.social📣 New #Communicable drops Mon 05 Oct!
Marc Bonten & Emily McDonald are joined by Valentijn Schweitzer & Sylvain Lother to discuss the use of macrolides in community-acquired pneumonia and how the available evidence informs clinical practice. Tune in!
@cmicomms.bsky.social🎙️ Just published 'Does oseltamivir harm critically ill patients? The REMAP-CAP results'
Hosted by Erin McCreary, PharmD & Josh Davis with invited guests Steve Webb & Steven Tong 🌟
Listen on #Communicable https://ow.ly/pJAO50ZOfK8 or on #Breakpoints https://ow.ly/p8Ti50ZOfK9
@cmicomms.bsky.social📣 New #Communicable / #Breakpoints drops Mon 21 Sep!
Erin McCreary, PharmD & Josh Davis are joined by Steve Webb & Steven Tong to discuss REMAP-CAP results suggesting that oseltamivir may harm critically ill patients, while also highlighting the importance and impact of RCTs.
@cmicomms.bsky.social🎙️ Just published Communicable E62: the 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis
Hosted by Emily McDonald & Josh Davis with invited guests Henning Bundgaard and Sami El-Dalati 🌟
Listen on #Communicable: https://share.transistor.fm/s/d5eb49ac
@cmicomms.bsky.social📣 New #Communicable drops Mon 03 Sep!
Emily McDonald & Josh Davis are joined by Henning Bundgaard & Sami El-Dalati to revisit the POET trial and discuss the ‘prose’ and cons of early oral switch for #endocarditis as well as challenges of implementing new evidence against long-standing dogma.